Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Imaging Diagnostic Systems, Inc. announced that a patent, 'Laser Imaging Apparatus Using Biomedical Markers That Bind to Cancer Cells' was issued to IMDS by the Chinese government. Laser optical breast cancer imaging systems firm Imaging Diagnostic Systems, Inc. (OTCBB:IMDS), announced that a patent, 'Laser Imaging Apparatus Using Biomedical Markers That Bind to Cancer Cells' was issued to IMDS by the Chinese government.

"We are very pleased to have been issued this patent in China and to extend our protection in another important market," stated Tim Hansen, IMDS Chief Executive Officer. "With this patent comes additional hope that breast cancer may someday be imaged and treated with light-activated compounds. Our current proprietary CT Laser Mammography System ( CTLM ®) is uniquely capable in these applications."

The Chinese patent, ZL 99 8 16608.1, joins the Australian patent 775069, issued July 2004; European patent EP01181511, issued June 2005; Hong Kong patent HK1043480, issued January 2006; and German patent DE69925869 issued May 2006. The patents, along with a previously issued Canadian patent, are equivalents of US patent 5,952,644. They protect the concept of imaging and activating a photodynamic therapy agent in an optical CT scanner, a combined diagnostic and therapeutic system.

This is the second patent issued to IMDS in China.